Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$46.88 USD
-1.26 (-2.62%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $46.86 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $69.57 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 253 |
Current Quarter EPS Est: | -0.61 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/20/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
9/4/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
9/3/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Not Available | Strong Buy |
8/21/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
8/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | Robert W. Baird & Co. | Brian P Skorney | Not Available | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.